60 Degrees Pharmaceuticals, Inc. (SXTPW) stock
SXTPWNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as SXTP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3033% below fair value
$0.03−0.00 (-0.38%)
Close on Oct 30, 2026Market cap $3.31MP/E –Yield –
60 Degrees Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
60 Degrees Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $2.33M, up 8.0% year over year. For fiscal 2025 it was $2.11M, down 57.8% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.11M | -57.8% |
| FY2024 | Dec 31, 2024 | $4.99M | +620.8% |
| FY2023 | Dec 31, 2023 | $691.77K | +31.6% |
| FY2022 | Dec 31, 2022 | $525.56K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $598.65K | +158.1% |
| Q1 FY2026 | Mar 31, 2026 | $281.46K | -24.1% |
| Q4 FY2025 | Dec 31, 2025 | $638.87K | +4.1% |
| Q3 FY2025 | Sep 30, 2025 | $809.78K | -13.9% |
| Q2 FY2025 | Jun 30, 2025 | $231.91K | -92.5% |
| Q1 FY2025 | Mar 31, 2025 | $370.81K | +10.0% |
| Q4 FY2024 | Dec 31, 2024 | $613.96K | +512.7% |
| Q3 FY2024 | Sep 30, 2024 | $940.06K | +256.5% |
| Q2 FY2024 | Jun 30, 2024 | $3.10M | +1418.3% |
| Q1 FY2024 | Mar 31, 2024 | $337.18K | +171.9% |
| Q4 FY2023 | Dec 31, 2023 | $100.20K | -50.8% |
| Q3 FY2023 | Sep 30, 2023 | $263.70K | +853.5% |
| Q2 FY2023 | Jun 30, 2023 | $203.87K | -11.9% |
| Q1 FY2023 | Mar 31, 2023 | $123.99K | – |
| Q4 FY2022 | Dec 31, 2022 | $203.46K | – |
| Q3 FY2022 | Sep 30, 2022 | $27.66K | – |
| Q2 FY2022 | Jun 30, 2022 | $231.39K | – |